Embla Medical Hf · OMXCOP:EMBLA
Embla Medical Hf — Q4 2024 Earnings Presentation
12 slides from Embla Medical Hf's earnings presentation, Feb 5, 2025
Slide 1: Q4/FY 2024 Conference Call
A leading global provider of innovative mobility solutions Q4/FY 2024 Conference Call Sveinn Sölvason, President and CEO G. Arna Sveinsdottir, CFO February 5, 2025 0
Slide 2: 2024 was an eventful year with several milestones reached
2024 was an eventful year with several milestones reached A blue background with white text Description automatically generated Growth’27 Entrance into Neuro Orthotics Launch of 3rd generation Our Growth’27 strategy on track Launch of Pro-Flex ForMotion, our new global with Fior & Gentz Naked Prosth
Slide 3: Key highlights Q4/FY 2024
Key highlights Q4/FY 2024 FY Performance Q4 Performance Operations External Local currency Local currency R&D progress in Q4 US Medicare coverage growth growth ✓ Bionic knees Navii® by Össur and expansion Icon® by College Park in limited +9% +8% • First K2 patients processed and launch; Great initia
Slide 4: Strong Americas and EMEA growth in Prosthetics & Neuro Orthotics
Strong Americas and EMEA growth in Prosthetics & Neuro Orthotics, while Patient Care in EMEA ended softer in Q4; mainly due to a strong comparable in prior quarter APAC APAC Q4: +3% Americas Q4: +7% 20 15% 150 8% 18 7% 10% 10% 6% 9% 16 USDm 100 5% 6% 4% 5% USDm 14 3% 50 2% 2% 12 0% 0% 1% 0 0% Q4'23
Slide 5: Prosthetics & Neuro Orthotics sales
Prosthetics & Neuro Orthotics sales % of total sales in Q4 Full year sales Full year growth Highlights ▪ EMEA: Continued strong performance in EMEA across European markets driven by solid volume 48% growth in key product categories, including bionics. 451 9% ▪ Americas: Strong performance in the reg
Slide 6: Bracing & Supports sales
Bracing & Supports sales % of total sales in Q4 Full year sales Full year growth Highlights ▪ EMEA: Sales growth driven by select product categories and key European markets. Bracing & Supports in EMEA has been impacted by increasing 148 1% competitive dynamics during the year. USD million organic g
Slide 7: Patient Care sales
Patient Care sales % of total sales in Q4 Full year sales Full year growth Highlights ▪ EMEA: EMEA growth impacted by decline in select markets; mainly due a strong comparable quarter 36% (12% growth in EMEA overall in Q4 2023) and timing. 294 5% All major markets contributed to growth on the full U
Slide 8: EBITDA margin expanding by 3%-points to 21% for the quarter
EBITDA margin expanding by 3%-points to 21% for the quarter vs. Q4’23; Expansion driven by higher Gross Profit margin and cost control in SG&A Gross Profit and Gross Profit margin Highlights USD million ▪ Gross Profit: Gross profit margin was 63% in Q4’24 vs. 61% in Q4 2023. The increase is supporte
Slide 9: Q4 Cash flow and leverage
Q4 Cash flow and leverage Capital expenditures and % of sales Free cash flow and % of sales Net Interest-Bearing Debt and Leverage USD million on actual rate USD million on actual rate USD million on actual rate 482 470 460 33 34 11 414 11 395 10 26 3.3x 9 3.1x 8 18 2.9x 15% 15% 2.8x 2.8x 13% 2.6x 2
Slide 10: 2025 Guidance
2025 Guidance FY 2025 Actual FY 2024 Sales growth 5-8% 6% Organic EBITDA margin 20-21% 20% Before special items For modeling purposes: Special items None 4 In USD million CAPEX 3-4% 5% % of sales Tax 23-24% 24% Effective tax rate Note: Potential impact as a result of the US trade tariffs has not bee
Slide 11: Q&A Key message from Q4/FY 2024
Q&A Key message from Q4/FY 2024 1. 2024 was an eventful year with several milestones reached, most notably the establishment of Embla Medical as our parent organization, starting to unite our patient care facilities under the ForMotion brand, and the acquisition of Fior & Gentz. Also, we delivered e
Slide 12: Contact our Investor Relations
Contact our Investor Relations Financial calendar and events February 5 2025 Interim report Q4 2024 and Annual Report 2024 February 5 2025 Q4/FY presentation and Q&A virtual (HCA Capital) February 5 2025 Q4/FY Road Show Iceland (EMBLA HQ) February 6 2025 Q4/FY Road Show Copenhagen (ABG) February 7 2